ORICORIC PharmaceuticalsORIC info
$8.43info-5.92%24h
Global rank12370
Market cap$459.87M
Change 7d-12.82%
YTD Performance-7.77%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    ORIC Pharmaceuticals (ORIC) Stock Overview

    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

    ORIC Stock Information

    Symbol
    ORIC
    Address
    240 East Grand AvenueSouth San Francisco, CA 94080United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://www.oricpharma.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    650 388 5600

    ORIC Pharmaceuticals (ORIC) Price Chart

    -
    Value:-

    ORIC Pharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $8.43
    N/A
    Market Cap
    $459.87M
    N/A
    Shares Outstanding
    54.55M
    N/A
    Employees
    93.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org